nodes	percent_of_prediction	percent_of_DWPC	metapath
Brompheniramine—CHRM4—Monoamine GPCRs—DRD4—conduct disorder	0.0267	0.0282	CbGpPWpGaD
Brompheniramine—CHRM5—Monoamine GPCRs—DRD4—conduct disorder	0.0256	0.027	CbGpPWpGaD
Brompheniramine—CHRM4—Amine ligand-binding receptors—DRD4—conduct disorder	0.0225	0.0237	CbGpPWpGaD
Brompheniramine—CHRM5—Amine ligand-binding receptors—DRD4—conduct disorder	0.0215	0.0227	CbGpPWpGaD
Brompheniramine—Chlorphenamine—SLC6A4—conduct disorder	0.0212	0.412	CrCbGaD
Brompheniramine—Promazine—DRD4—conduct disorder	0.0206	0.402	CrCbGaD
Brompheniramine—HRH1—Monoamine GPCRs—DRD4—conduct disorder	0.0181	0.0191	CbGpPWpGaD
Brompheniramine—CHRM1—Monoamine GPCRs—DRD4—conduct disorder	0.018	0.019	CbGpPWpGaD
Brompheniramine—CHRM3—Monoamine GPCRs—DRD4—conduct disorder	0.018	0.019	CbGpPWpGaD
Brompheniramine—CHRM2—Monoamine GPCRs—DRD4—conduct disorder	0.0178	0.0188	CbGpPWpGaD
Brompheniramine—CHRM4—Monoamine GPCRs—HTR2A—conduct disorder	0.0175	0.0184	CbGpPWpGaD
Brompheniramine—CHRM5—Monoamine GPCRs—HTR2A—conduct disorder	0.0167	0.0176	CbGpPWpGaD
Brompheniramine—HRH1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0152	0.016	CbGpPWpGaD
Brompheniramine—CHRM1—Amine ligand-binding receptors—DRD4—conduct disorder	0.0152	0.016	CbGpPWpGaD
Brompheniramine—CHRM3—Amine ligand-binding receptors—DRD4—conduct disorder	0.0151	0.0159	CbGpPWpGaD
Brompheniramine—CHRM2—Amine ligand-binding receptors—DRD4—conduct disorder	0.015	0.0158	CbGpPWpGaD
Brompheniramine—CHRM4—Amine ligand-binding receptors—HTR2A—conduct disorder	0.0147	0.0155	CbGpPWpGaD
Brompheniramine—CHRM5—Amine ligand-binding receptors—HTR2A—conduct disorder	0.014	0.0148	CbGpPWpGaD
Brompheniramine—HRH1—Monoamine GPCRs—HTR2A—conduct disorder	0.0118	0.0124	CbGpPWpGaD
Brompheniramine—CHRM1—Monoamine GPCRs—HTR2A—conduct disorder	0.0118	0.0124	CbGpPWpGaD
Brompheniramine—CHRM3—Monoamine GPCRs—HTR2A—conduct disorder	0.0117	0.0124	CbGpPWpGaD
Brompheniramine—CHRM2—Monoamine GPCRs—HTR2A—conduct disorder	0.0116	0.0122	CbGpPWpGaD
Brompheniramine—CHRM4—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0115	0.0121	CbGpPWpGaD
Brompheniramine—CHRM5—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.011	0.0116	CbGpPWpGaD
Brompheniramine—CYP2C19—Melatonin metabolism and effects—MAOA—conduct disorder	0.0104	0.0109	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.0103	0.0108	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—GABRA2—conduct disorder	0.0102	0.0107	CbGpPWpGaD
Brompheniramine—HRH1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00992	0.0105	CbGpPWpGaD
Brompheniramine—CHRM1—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00989	0.0104	CbGpPWpGaD
Brompheniramine—CHRM3—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00986	0.0104	CbGpPWpGaD
Brompheniramine—CHRM2—Amine ligand-binding receptors—HTR2A—conduct disorder	0.00976	0.0103	CbGpPWpGaD
Brompheniramine—CYP2D6—Melatonin metabolism and effects—MAOA—conduct disorder	0.00954	0.0101	CbGpPWpGaD
Brompheniramine—Promazine—HTR2A—conduct disorder	0.00952	0.186	CrCbGaD
Brompheniramine—CYP3A4—Estrogen metabolism—COMT—conduct disorder	0.0092	0.0097	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Other—DRD4—conduct disorder	0.00799	0.00842	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Other—DRD4—conduct disorder	0.00791	0.00834	CbGpPWpGaD
Brompheniramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.0079	0.00832	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00773	0.00815	CbGpPWpGaD
Brompheniramine—CHRM1—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00773	0.00815	CbGpPWpGaD
Brompheniramine—CHRM3—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.0077	0.00812	CbGpPWpGaD
Brompheniramine—CHRM2—Regulation of Actin Cytoskeleton—WASF1—conduct disorder	0.00763	0.00804	CbGpPWpGaD
Brompheniramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00756	0.00797	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.0063	0.00664	CbGpPWpGaD
Brompheniramine—CYP2B6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00622	0.00656	CbGpPWpGaD
Brompheniramine—CYP2E1—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00609	0.00642	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—CGA—conduct disorder	0.00601	0.00634	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—CGA—conduct disorder	0.00576	0.00607	CbGpPWpGaD
Brompheniramine—CHRM4—G alpha (i) signalling events—DRD4—conduct disorder	0.00556	0.00586	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—SLC6A4—conduct disorder	0.00546	0.00576	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00534	0.00563	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00532	0.00561	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00531	0.00559	CbGpPWpGaD
Brompheniramine—CYP2C8—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00527	0.00555	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—CGA—conduct disorder	0.00526	0.00554	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Other—HTR2A—conduct disorder	0.00521	0.00549	CbGpPWpGaD
Brompheniramine—CHRM4—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00516	0.00544	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Other—HTR2A—conduct disorder	0.00516	0.00544	CbGpPWpGaD
Brompheniramine—CHRM5—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00494	0.00521	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—COMT—conduct disorder	0.00489	0.00515	CbGpPWpGaD
Brompheniramine—KCNH2—Neuronal System—MAOA—conduct disorder	0.00485	0.00512	CbGpPWpGaD
Brompheniramine—CYP2C19—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.0047	0.00495	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—SLC6A4—conduct disorder	0.00452	0.00476	CbGpPWpGaD
Brompheniramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00442	0.00466	CbGpPWpGaD
Brompheniramine—CYP2D6—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00432	0.00456	CbGpPWpGaD
Brompheniramine—CYP2C9—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00429	0.00452	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—DRD4—conduct disorder	0.00425	0.00448	CbGpPWpGaD
Brompheniramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00423	0.00446	CbGpPWpGaD
Brompheniramine—HRH1—IL-4 Signaling Pathway—EP300—conduct disorder	0.00422	0.00445	CbGpPWpGaD
Brompheniramine—CHRM5—G alpha (q) signalling events—HTR2A—conduct disorder	0.00417	0.0044	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—MAOA—conduct disorder	0.00411	0.00433	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—CGA—conduct disorder	0.00407	0.00429	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—CGA—conduct disorder	0.00405	0.00427	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—CGA—conduct disorder	0.00404	0.00426	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—CGA—conduct disorder	0.004	0.00422	CbGpPWpGaD
Brompheniramine—CHRM5—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00373	0.00393	CbGpPWpGaD
Brompheniramine—CHRM2—G alpha (i) signalling events—DRD4—conduct disorder	0.0037	0.0039	CbGpPWpGaD
Brompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00349	0.00368	CbGpPWpGaD
Brompheniramine—CHRM1—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00348	0.00367	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00347	0.00366	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Class A Rhodopsin-like—DRD4—conduct disorder	0.00344	0.00362	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—CGA—conduct disorder	0.0034	0.00358	CbGpPWpGaD
Brompheniramine—CHRM4—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00337	0.00355	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—DRD4—conduct disorder	0.00337	0.00355	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—HTR2A—conduct disorder	0.00335	0.00353	CbGpPWpGaD
Brompheniramine—KCNH2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00334	0.00352	CbGpPWpGaD
Brompheniramine—CYP2B6—Biological oxidations—COMT—conduct disorder	0.00333	0.00351	CbGpPWpGaD
Brompheniramine—CYP2B6—Biological oxidations—MAOA—conduct disorder	0.0033	0.00348	CbGpPWpGaD
Brompheniramine—CYP2B6—Metapathway biotransformation—COMT—conduct disorder	0.00328	0.00346	CbGpPWpGaD
Brompheniramine—CYP2E1—Biological oxidations—COMT—conduct disorder	0.00326	0.00344	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—CGA—conduct disorder	0.00325	0.00343	CbGpPWpGaD
Brompheniramine—CYP2E1—Biological oxidations—MAOA—conduct disorder	0.00324	0.00341	CbGpPWpGaD
Brompheniramine—CHRM5—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00323	0.0034	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—DRD4—conduct disorder	0.00322	0.0034	CbGpPWpGaD
Brompheniramine—CYP2E1—Metapathway biotransformation—COMT—conduct disorder	0.00321	0.00339	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—CGA—conduct disorder	0.00309	0.00325	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00299	0.00315	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00298	0.00314	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00297	0.00313	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—CGA—conduct disorder	0.00296	0.00312	CbGpPWpGaD
Brompheniramine—HRH1—G alpha (q) signalling events—HTR2A—conduct disorder	0.00295	0.00311	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—DRD4—conduct disorder	0.00294	0.0031	CbGpPWpGaD
Brompheniramine—CHRM1—G alpha (q) signalling events—HTR2A—conduct disorder	0.00294	0.0031	CbGpPWpGaD
Brompheniramine—CHRM3—G alpha (q) signalling events—HTR2A—conduct disorder	0.00293	0.00309	CbGpPWpGaD
Brompheniramine—CHRM4—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00289	0.00304	CbGpPWpGaD
Brompheniramine—CYP3A4—Phase 1 - Functionalization of compounds—MAOA—conduct disorder	0.00283	0.00298	CbGpPWpGaD
Brompheniramine—CYP2C8—Biological oxidations—COMT—conduct disorder	0.00282	0.00297	CbGpPWpGaD
Brompheniramine—CYP2C8—Biological oxidations—MAOA—conduct disorder	0.0028	0.00295	CbGpPWpGaD
Brompheniramine—CYP2C8—Metapathway biotransformation—COMT—conduct disorder	0.00278	0.00293	CbGpPWpGaD
Brompheniramine—CHRM5—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00276	0.00291	CbGpPWpGaD
Brompheniramine—HRH1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00264	0.00278	CbGpPWpGaD
Brompheniramine—CHRM1—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00263	0.00277	CbGpPWpGaD
Brompheniramine—CHRM3—Gastrin-CREB signalling pathway via PKC and MAPK—HTR2A—conduct disorder	0.00262	0.00276	CbGpPWpGaD
Brompheniramine—CYP2C19—Biological oxidations—COMT—conduct disorder	0.00251	0.00265	CbGpPWpGaD
Brompheniramine—CYP2C19—Biological oxidations—MAOA—conduct disorder	0.0025	0.00263	CbGpPWpGaD
Brompheniramine—CYP2C19—Metapathway biotransformation—COMT—conduct disorder	0.00248	0.00261	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.0024	0.00253	CbGpPWpGaD
Brompheniramine—CYP2D6—Biological oxidations—COMT—conduct disorder	0.00231	0.00244	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—CGA—conduct disorder	0.0023	0.00242	CbGpPWpGaD
Brompheniramine—CYP2D6—Biological oxidations—MAOA—conduct disorder	0.0023	0.00242	CbGpPWpGaD
Brompheniramine—CYP2C9—Biological oxidations—COMT—conduct disorder	0.00229	0.00242	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—CGA—conduct disorder	0.00229	0.00242	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—CGA—conduct disorder	0.00228	0.00241	CbGpPWpGaD
Brompheniramine—CYP2D6—Metapathway biotransformation—COMT—conduct disorder	0.00228	0.0024	CbGpPWpGaD
Brompheniramine—HRH1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00228	0.0024	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—DRD4—conduct disorder	0.00228	0.0024	CbGpPWpGaD
Brompheniramine—CYP2C9—Biological oxidations—MAOA—conduct disorder	0.00228	0.0024	CbGpPWpGaD
Brompheniramine—CHRM1—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00227	0.00239	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—DRD4—conduct disorder	0.00227	0.00239	CbGpPWpGaD
Brompheniramine—CHRM3—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00226	0.00239	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—DRD4—conduct disorder	0.00226	0.00239	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—CGA—conduct disorder	0.00226	0.00238	CbGpPWpGaD
Brompheniramine—CYP2C9—Metapathway biotransformation—COMT—conduct disorder	0.00226	0.00238	CbGpPWpGaD
Brompheniramine—CHRM2—GPCRs, Class A Rhodopsin-like—HTR2A—conduct disorder	0.00224	0.00236	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—DRD4—conduct disorder	0.00224	0.00236	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR ligand binding—HTR2A—conduct disorder	0.0022	0.00232	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00214	0.00225	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR ligand binding—HTR2A—conduct disorder	0.0021	0.00222	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—CGA—conduct disorder	0.00209	0.0022	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—CGA—conduct disorder	0.00208	0.00219	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—CGA—conduct disorder	0.00207	0.00219	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—CGA—conduct disorder	0.00205	0.00217	CbGpPWpGaD
Brompheniramine—HRH1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00195	0.00206	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism of lipids and lipoproteins—CGA—conduct disorder	0.00195	0.00206	CbGpPWpGaD
Brompheniramine—CHRM1—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00195	0.00205	CbGpPWpGaD
Brompheniramine—CHRM3—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00194	0.00204	CbGpPWpGaD
Brompheniramine—CHRM2—Class A/1 (Rhodopsin-like receptors)—HTR2A—conduct disorder	0.00192	0.00202	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—DRD4—conduct disorder	0.0019	0.00201	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—CGA—conduct disorder	0.00182	0.00192	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—DRD4—conduct disorder	0.00182	0.00192	CbGpPWpGaD
Brompheniramine—CHRM2—SIDS Susceptibility Pathways—EP300—conduct disorder	0.00178	0.00187	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—CGA—conduct disorder	0.00175	0.00184	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—DRD4—conduct disorder	0.00173	0.00182	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—DRD4—conduct disorder	0.00165	0.00174	CbGpPWpGaD
Brompheniramine—CYP3A4—Biological oxidations—COMT—conduct disorder	0.00151	0.00159	CbGpPWpGaD
Brompheniramine—CYP3A4—Biological oxidations—MAOA—conduct disorder	0.0015	0.00158	CbGpPWpGaD
Brompheniramine—CYP3A4—Metapathway biotransformation—COMT—conduct disorder	0.00149	0.00157	CbGpPWpGaD
Brompheniramine—HRH1—GPCR ligand binding—HTR2A—conduct disorder	0.00149	0.00157	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR ligand binding—HTR2A—conduct disorder	0.00148	0.00156	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR ligand binding—HTR2A—conduct disorder	0.00148	0.00156	CbGpPWpGaD
Brompheniramine—CHRM1—Circadian rythm related genes—EP300—conduct disorder	0.00147	0.00155	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—CGA—conduct disorder	0.00147	0.00154	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR ligand binding—HTR2A—conduct disorder	0.00146	0.00154	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—WASF1—conduct disorder	0.00146	0.00154	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—WASF1—conduct disorder	0.0014	0.00147	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—DRD4—conduct disorder	0.00129	0.00136	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—DRD4—conduct disorder	0.00128	0.00135	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—DRD4—conduct disorder	0.00128	0.00135	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—DRD4—conduct disorder	0.00127	0.00134	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—CGA—conduct disorder	0.00126	0.00133	CbGpPWpGaD
Brompheniramine—CHRM4—GPCR downstream signaling—HTR2A—conduct disorder	0.00124	0.00131	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—CGA—conduct disorder	0.00123	0.0013	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—CGA—conduct disorder	0.00123	0.0013	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—CGA—conduct disorder	0.00123	0.0013	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—CGA—conduct disorder	0.00123	0.00129	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—CGA—conduct disorder	0.00121	0.00128	CbGpPWpGaD
Brompheniramine—CHRM5—GPCR downstream signaling—HTR2A—conduct disorder	0.00119	0.00125	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—DRD4—conduct disorder	0.00117	0.00123	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—DRD4—conduct disorder	0.00117	0.00123	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—DRD4—conduct disorder	0.00116	0.00122	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—DRD4—conduct disorder	0.00115	0.00121	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling by GPCR—HTR2A—conduct disorder	0.00113	0.00119	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling by GPCR—HTR2A—conduct disorder	0.00108	0.00114	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—CGA—conduct disorder	0.00107	0.00113	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—DRD4—conduct disorder	0.00102	0.00108	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—WASF1—conduct disorder	0.000988	0.00104	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—WASF1—conduct disorder	0.000985	0.00104	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—WASF1—conduct disorder	0.000982	0.00104	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—DRD4—conduct disorder	0.000978	0.00103	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—WASF1—conduct disorder	0.000972	0.00103	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—CGA—conduct disorder	0.000953	0.001	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—CGA—conduct disorder	0.000876	0.000924	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—CGA—conduct disorder	0.000869	0.000916	CbGpPWpGaD
Brompheniramine—HRH1—GPCR downstream signaling—HTR2A—conduct disorder	0.00084	0.000885	CbGpPWpGaD
Brompheniramine—CHRM1—GPCR downstream signaling—HTR2A—conduct disorder	0.000837	0.000883	CbGpPWpGaD
Brompheniramine—CHRM3—GPCR downstream signaling—HTR2A—conduct disorder	0.000835	0.00088	CbGpPWpGaD
Brompheniramine—CHRM2—GPCR downstream signaling—HTR2A—conduct disorder	0.000826	0.000871	CbGpPWpGaD
Brompheniramine—HRH1—Signaling by GPCR—HTR2A—conduct disorder	0.000763	0.000804	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling by GPCR—HTR2A—conduct disorder	0.00076	0.000801	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling by GPCR—HTR2A—conduct disorder	0.000758	0.000799	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling by GPCR—HTR2A—conduct disorder	0.000751	0.000791	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—DRD4—conduct disorder	0.000691	0.000728	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—DRD4—conduct disorder	0.000688	0.000726	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—DRD4—conduct disorder	0.000686	0.000723	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—DRD4—conduct disorder	0.00068	0.000716	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—HTR2A—conduct disorder	0.000666	0.000702	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—COMT—conduct disorder	0.000661	0.000697	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—MAOA—conduct disorder	0.000657	0.000692	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—HTR2A—conduct disorder	0.000638	0.000672	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—CGA—conduct disorder	0.000573	0.000604	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—COMT—conduct disorder	0.000569	0.0006	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—MAOA—conduct disorder	0.000565	0.000596	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—COMT—conduct disorder	0.000557	0.000588	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—MAOA—conduct disorder	0.000553	0.000583	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—COMT—conduct disorder	0.000482	0.000508	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—MAOA—conduct disorder	0.000478	0.000504	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000464	0.000489	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—HTR2A—conduct disorder	0.000451	0.000475	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—HTR2A—conduct disorder	0.000449	0.000473	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—HTR2A—conduct disorder	0.000448	0.000472	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—HTR2A—conduct disorder	0.000443	0.000467	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—COMT—conduct disorder	0.00043	0.000453	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—MAOA—conduct disorder	0.000427	0.00045	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000414	0.000436	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—COMT—conduct disorder	0.000396	0.000417	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—MAOA—conduct disorder	0.000393	0.000414	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—COMT—conduct disorder	0.000392	0.000413	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—MAOA—conduct disorder	0.000389	0.00041	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism of lipids and lipoproteins—EP300—conduct disorder	0.000378	0.000398	CbGpPWpGaD
Brompheniramine—CHRM4—Signaling Pathways—EP300—conduct disorder	0.000353	0.000372	CbGpPWpGaD
Brompheniramine—CHRM5—Signaling Pathways—EP300—conduct disorder	0.000338	0.000356	CbGpPWpGaD
Brompheniramine—CHRM3—Metabolism—EP300—conduct disorder	0.000284	0.000299	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—COMT—conduct disorder	0.000259	0.000273	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—MAOA—conduct disorder	0.000257	0.000271	CbGpPWpGaD
Brompheniramine—CYP2B6—Metabolism—EP300—conduct disorder	0.000244	0.000257	CbGpPWpGaD
Brompheniramine—CYP2E1—Metabolism—EP300—conduct disorder	0.000239	0.000252	CbGpPWpGaD
Brompheniramine—HRH1—Signaling Pathways—EP300—conduct disorder	0.000239	0.000252	CbGpPWpGaD
Brompheniramine—CHRM1—Signaling Pathways—EP300—conduct disorder	0.000238	0.000251	CbGpPWpGaD
Brompheniramine—CHRM3—Signaling Pathways—EP300—conduct disorder	0.000237	0.00025	CbGpPWpGaD
Brompheniramine—CHRM2—Signaling Pathways—EP300—conduct disorder	0.000235	0.000248	CbGpPWpGaD
Brompheniramine—CYP2C8—Metabolism—EP300—conduct disorder	0.000207	0.000218	CbGpPWpGaD
Brompheniramine—CYP2C19—Metabolism—EP300—conduct disorder	0.000184	0.000194	CbGpPWpGaD
Brompheniramine—CYP2D6—Metabolism—EP300—conduct disorder	0.00017	0.000179	CbGpPWpGaD
Brompheniramine—CYP2C9—Metabolism—EP300—conduct disorder	0.000168	0.000177	CbGpPWpGaD
Brompheniramine—CYP3A4—Metabolism—EP300—conduct disorder	0.000111	0.000117	CbGpPWpGaD
